395 related articles for article (PubMed ID: 25849602)
1. Gleason 6 Prostate Cancer: Translating Biology into Population Health.
Eggener SE; Badani K; Barocas DA; Barrisford GW; Cheng JS; Chin AI; Corcoran A; Epstein JI; George AK; Gupta GN; Hayn MH; Kauffman EC; Lane B; Liss MA; Mirza M; Morgan TM; Moses K; Nepple KG; Preston MA; Rais-Bahrami S; Resnick MJ; Siddiqui MM; Silberstein J; Singer EA; Sonn GA; Sprenkle P; Stratton KL; Taylor J; Tomaszewski J; Tollefson M; Vickers A; White WM; Lowrance WT
J Urol; 2015 Sep; 194(3):626-34. PubMed ID: 25849602
[TBL] [Abstract][Full Text] [Related]
2. Contemporary grading for prostate cancer: implications for patient care.
Brimo F; Montironi R; Egevad L; Erbersdobler A; Lin DW; Nelson JB; Rubin MA; van der Kwast T; Amin M; Epstein JI
Eur Urol; 2013 May; 63(5):892-901. PubMed ID: 23092544
[TBL] [Abstract][Full Text] [Related]
3. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
4. Active Surveillance is an Appropriate Management Strategy for a Proportion of Men Diagnosed with Prostate Cancer by Prostate Specific Antigen Testing.
Overholser S; Nielsen M; Torkko K; Cwilka D; Weaver B; Shi X; Leach RJ; Hernandez J; Huang T; Thompson IM; Thompson IM
J Urol; 2015 Sep; 194(3):680-4. PubMed ID: 25636657
[TBL] [Abstract][Full Text] [Related]
5. An evidence review of active surveillance in men with localized prostate cancer.
Ip S; Dahabreh IJ; Chung M; Yu WW; Balk EM; Iovin RC; Mathew P; Luongo T; Dvorak T; Lau J
Evid Rep Technol Assess (Full Rep); 2011 Dec; (204):1-341. PubMed ID: 23126653
[TBL] [Abstract][Full Text] [Related]
6. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
[TBL] [Abstract][Full Text] [Related]
7. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.
Epstein JI; Egevad L; Amin MB; Delahunt B; Srigley JR; Humphrey PA;
Am J Surg Pathol; 2016 Feb; 40(2):244-52. PubMed ID: 26492179
[TBL] [Abstract][Full Text] [Related]
8. Clarifying uncertainty regarding detection and treatment of early-stage prostate cancer.
Wilt TJ
Semin Urol Oncol; 2002 Feb; 20(1):10-7. PubMed ID: 11828353
[TBL] [Abstract][Full Text] [Related]
9. Do Gleason patterns 3 and 4 prostate cancer represent separate disease states?
Lavery HJ; Droller MJ
J Urol; 2012 Nov; 188(5):1667-75. PubMed ID: 22998919
[TBL] [Abstract][Full Text] [Related]
10. Gleason inflation 1998-2011: a registry study of 97,168 men.
Danneman D; Drevin L; Robinson D; Stattin P; Egevad L
BJU Int; 2015 Feb; 115(2):248-55. PubMed ID: 24552193
[TBL] [Abstract][Full Text] [Related]
11. Estimating the individual benefit of immediate treatment or active surveillance for prostate cancer after screen-detection in older (65+) men.
de Carvalho TM; Heijnsdijk EA; de Koning HJ
Int J Cancer; 2016 May; 138(10):2522-8. PubMed ID: 26695380
[TBL] [Abstract][Full Text] [Related]
12. Appropriateness Criteria for Active Surveillance of Prostate Cancer.
Cher ML; Dhir A; Auffenberg GB; Linsell S; Gao Y; Rosenberg B; Jafri SM; Klotz L; Miller DC; Ghani KR; Bernstein SJ; Montie JE; Lane BR;
J Urol; 2017 Jan; 197(1):67-74. PubMed ID: 27422298
[TBL] [Abstract][Full Text] [Related]
13. Expanded criteria to identify men eligible for active surveillance of low risk prostate cancer at Johns Hopkins: a preliminary analysis.
Reese AC; Landis P; Han M; Epstein JI; Carter HB
J Urol; 2013 Dec; 190(6):2033-8. PubMed ID: 23680308
[TBL] [Abstract][Full Text] [Related]
14. Defining the threshold for significant versus insignificant prostate cancer.
Van der Kwast TH; Roobol MJ
Nat Rev Urol; 2013 Aug; 10(8):473-82. PubMed ID: 23712205
[TBL] [Abstract][Full Text] [Related]
15. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
16. Metastatic Prostate Cancer in Men Initially Treated with Active Surveillance.
Yamamoto T; Musunuru HB; Vesprini D; Zhang L; Ghanem G; Loblaw A; Klotz L
J Urol; 2016 May; 195(5):1409-1414. PubMed ID: 26707510
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
[TBL] [Abstract][Full Text] [Related]
18. Histopathological prostate cancer characteristics at radical prostatectomy after population based screening.
Hoedemaeker RF; Rietbergen JB; Kranse R; Schröder FH; van der Kwast TH
J Urol; 2000 Aug; 164(2):411-5. PubMed ID: 10893598
[TBL] [Abstract][Full Text] [Related]
19. Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study.
Margel D; Nandy I; Wilson TH; Castro R; Fleshner N
J Urol; 2013 Dec; 190(6):2039-45. PubMed ID: 23820059
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
